Growth Metrics

Quest Diagnostics (DGX) EPS (Weighted Average and Diluted) (2016 - 2025)

Quest Diagnostics (DGX) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $2.18 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 11.79% to $2.18 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.75 through Dec 2025, up 13.78% year-over-year, with the annual reading at $8.75 for FY2025, 13.78% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $2.18 in Q4 2025 for Quest Diagnostics, up from $2.16 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.96 in Q2 2021 to a low of $0.92 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $2.37 across 5 years, with a median of $2.04 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 373.97% in 2021 and later crashed 70.7% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $3.14 in 2021, then plummeted by 70.7% to $0.92 in 2022, then surged by 84.78% to $1.7 in 2023, then increased by 14.71% to $1.95 in 2024, then rose by 11.79% to $2.18 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for DGX at $2.18 in Q4 2025, $2.16 in Q3 2025, and $2.47 in Q2 2025.